Cargando…
Designer drugs 2015: assessment and management
Recent designer drugs, also known as “legal highs,” include substituted cathinones (e.g., mephedrone, methylone, and methylenedioxypyrovalerone, often referred to as “bath salts”); synthetic cannabinoids (SCs; e.g., Spice); and synthetic hallucinogens (25I-NBOMe, or N-bomb). Compound availability ha...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4422150/ https://www.ncbi.nlm.nih.gov/pubmed/25928069 http://dx.doi.org/10.1186/s13722-015-0024-7 |
_version_ | 1782370015629017088 |
---|---|
author | Weaver, Michael F Hopper, John A Gunderson, Erik W |
author_facet | Weaver, Michael F Hopper, John A Gunderson, Erik W |
author_sort | Weaver, Michael F |
collection | PubMed |
description | Recent designer drugs, also known as “legal highs,” include substituted cathinones (e.g., mephedrone, methylone, and methylenedioxypyrovalerone, often referred to as “bath salts”); synthetic cannabinoids (SCs; e.g., Spice); and synthetic hallucinogens (25I-NBOMe, or N-bomb). Compound availability has evolved rapidly to evade legal regulation and detection by routine drug testing. Young adults are the primary users, but trends are changing rapidly; use has become popular among members of the military. Acute toxicity is common and often manifests with a constellation of psychiatric and medical effects, which may be severe (e.g., anxiety, agitation, psychosis, and tachycardia), and multiple deaths have been reported with each of these types of designer drugs. Clinicians should keep designer drugs in mind when evaluating substance use in young adults or in anyone presenting with acute neuropsychiatric complaints. Treatment of acute intoxication involves supportive care targeting manifesting signs and symptoms. Long-term treatment of designer drug use disorder can be challenging and is complicated by a lack of evidence to guide treatment. |
format | Online Article Text |
id | pubmed-4422150 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-44221502015-05-07 Designer drugs 2015: assessment and management Weaver, Michael F Hopper, John A Gunderson, Erik W Addict Sci Clin Pract Review Recent designer drugs, also known as “legal highs,” include substituted cathinones (e.g., mephedrone, methylone, and methylenedioxypyrovalerone, often referred to as “bath salts”); synthetic cannabinoids (SCs; e.g., Spice); and synthetic hallucinogens (25I-NBOMe, or N-bomb). Compound availability has evolved rapidly to evade legal regulation and detection by routine drug testing. Young adults are the primary users, but trends are changing rapidly; use has become popular among members of the military. Acute toxicity is common and often manifests with a constellation of psychiatric and medical effects, which may be severe (e.g., anxiety, agitation, psychosis, and tachycardia), and multiple deaths have been reported with each of these types of designer drugs. Clinicians should keep designer drugs in mind when evaluating substance use in young adults or in anyone presenting with acute neuropsychiatric complaints. Treatment of acute intoxication involves supportive care targeting manifesting signs and symptoms. Long-term treatment of designer drug use disorder can be challenging and is complicated by a lack of evidence to guide treatment. BioMed Central 2015-03-25 2015 /pmc/articles/PMC4422150/ /pubmed/25928069 http://dx.doi.org/10.1186/s13722-015-0024-7 Text en © Weaver et al.; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Review Weaver, Michael F Hopper, John A Gunderson, Erik W Designer drugs 2015: assessment and management |
title | Designer drugs 2015: assessment and management |
title_full | Designer drugs 2015: assessment and management |
title_fullStr | Designer drugs 2015: assessment and management |
title_full_unstemmed | Designer drugs 2015: assessment and management |
title_short | Designer drugs 2015: assessment and management |
title_sort | designer drugs 2015: assessment and management |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4422150/ https://www.ncbi.nlm.nih.gov/pubmed/25928069 http://dx.doi.org/10.1186/s13722-015-0024-7 |
work_keys_str_mv | AT weavermichaelf designerdrugs2015assessmentandmanagement AT hopperjohna designerdrugs2015assessmentandmanagement AT gundersonerikw designerdrugs2015assessmentandmanagement |